Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- NanoCarrier, Axcelead Forge JV to Develop mRNA-Driven Articular Cartilage Drug
April 27, 2021
- Sota Yamaguchi to Assume New ASKA President Post in June
April 27, 2021
- Canada Starts Review of Medicago’s Rolling Submission for COVID-19 Vaccine
April 27, 2021
- Sumitomo Dainippon Ups FY2020 Guidance
April 26, 2021
- Lenvima/Keytruda Combo Filed for Uterine Body Cancer in Japan
April 26, 2021
- Gilead Seeks UC Indication for JAK Inhibitor Jyseleca in Japan
April 26, 2021
- Takeda’s ALK Inhibitor Alunbrig Now Available in Japan
April 26, 2021
- Santen to Launch New Plant in China, Commence Operations in 2025
April 26, 2021
- Delta-Fly/Nippon Chemiphar’s TME Therapy Now in Japan PII Trial
April 23, 2021
- Nichi-Iko Reveals Possible Supply Delays for 164 Products, Stirs Confusion at Peers, Customers
April 23, 2021
- Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports
April 23, 2021
- Stella Pharma Goes Public on TSE
April 23, 2021
- Mitsubishi Tanabe Files Tardive Dyskinesia Drug in Japan
April 23, 2021
- Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
- Takeda Teams Up with IT Startup for AI-Driven Early HAE Detection
April 23, 2021
- Kobayashi Kako Starts Recalling Products Subject to Approval Revocation
April 22, 2021
- Calquence, Adlumiz, Zymso Now Available in Japan
April 22, 2021
- Supply Delays Likely for 160 Nichi-Iko Products despite Biz Suspension Lifted
April 22, 2021
- Fujifilm Launches New Japanese Avigan PIII Study for COVID-19
April 22, 2021
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…